Abstract
The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Reviews on Recent Clinical Trials
Title:Gut Microbiota and Alcoholic Liver Disease
Volume: 11 Issue: 3
Author(s): Emidio Scarpellini, Mariana Forlino, Marinella Lupo, Carlo Rasetti, Giammarco Fava, Ludovico Abenavoli and Adriano De Santis
Affiliation:
Keywords: Gut microbiota, alcohol, intestinal permeability, lipopolysaccharide, antibiotics, probiotics.
Abstract: The gut–liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
Export Options
About this article
Cite this article as:
Scarpellini Emidio, Forlino Mariana, Lupo Marinella, Rasetti Carlo, Fava Giammarco, Abenavoli Ludovico and De Santis Adriano, Gut Microbiota and Alcoholic Liver Disease, Reviews on Recent Clinical Trials 2016; 11 (3) . https://dx.doi.org/10.2174/1574887111666160810100538
DOI https://dx.doi.org/10.2174/1574887111666160810100538 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Rare Case Report of Inguinal Herniation with Urinary Bladder as its Content
New Emirates Medical Journal Editorial [Hot Topic: Targeting Cell Migration - The Next Generation Blockbusters (Guest Editors: Amanda E.I. Proudfoot, Marie Kosco-Vilbois and Zoe Johnson)]
Current Immunology Reviews (Discontinued) Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry A Potential Role of Diet in Modulating Peroxisome Proliferator-Activated Receptor (PPAR)-Mediated Signalling in Arthritis
Current Rheumatology Reviews Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies MR Imaging Findings of Uterine Cervical Carcinoma
Current Medical Imaging Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism Pharmacophore Modeling in Drug Discovery and Development: An Overview
Medicinal Chemistry The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Effects of Quinone Derivatives, such as 1,4-Naphthoquinone, on DNA Polymerase Inhibition and Anti-Inflammatory Action
Medicinal Chemistry The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry A Review of Surgical Options to Preserve Fertility in the Treatment of Early Cervical Cancer
Current Women`s Health Reviews Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Current Drug Targets - Inflammation & Allergy A Retrospective Study on <i>Gloriosa superba</i> and Its Main Active Constituents
The Natural Products Journal The Chemical Composition of Essential Oil of Warionea saharae Benth & Coss.(Fam.Asteraceae) from Southern Algeria
Current Bioactive Compounds Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry An update on Anti-inflammatory Compounds: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry